Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|October 2007||12/9/2007||Pilot Study of Growth Hormon to Treat SMA Typ II and III||Can Treatment With Human Growth Hormone Increase Strength in Spinal Muscular Atrophy Type II and III?||Muscular Atrophy, Spinal||Drug: somatotropin;Drug: Placebo||University Hospital Freiburg||Novo Nordisk A/S||Completed||6 Years||35 Years||Both||20||Phase 2||Germany|
|09/01/2006||21/11/2005||Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GH||Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GH||Spinal muscular atrophy (SMA) is an autosomal recessive disease. Due to the genetic defect, a molecule called spinal motor neuron” (SMN) protein is lacking, resulting in muscle weakness. In SMAs muscle weakness is found most often at the level of proximal muscles. The disease is life-threatening and chronically debilitating.||Trade Name: Norditropin SimpleXx|
Product Name: Norditropin SimpleXx 15 mg/1.5 ml
Product Code: GH
INN or Proposed INN: Somatropin
Other descriptive name: Norditropin SimpleXx
|Klinik Neuropädiatrie und Muskelkrankheiten||NULL||Not Recruiting||Female: yes|